ArticlePloS one2013
Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 5 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Pooled it
- Global research progress of visceral hypersensitivity and irritable bowel syndrome: bibliometrics and visualized analysis.Frontiers in pharmacology · 2023Pooled it
- Enterochromaffin Cells: Sentinels to Gut Microbiota in Hyperalgesia?Frontiers in cellular and infection microbiology · 2021Pooled it
- Systematic review and meta-analysis: Efficacy of patented probiotic, VSL#3, in irritable bowel syndrome.Neurogastroenterology and motility · 2018Pooled it
- Modulation of immunity and inflammatory gene expression in the gut, in inflammatory diseases of the gut and in the liver by probiotics.World journal of gastroenterology · 2014Pooled it
- Effects of supplementing with Saccharomyces boulardii on vonoprazan-amoxicillin dual therapy for naive Helicobacter pylori infection: a randomized controlled trial.BMC gastroenterology · 2026Trial
- A prospective, interventional, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Bacillus coagulans LBSC in the treatment of acute diarrhea with abdominal discomfort.European journal of clinical pharmacology · 2019Trial
- Trial
- The Role of the TRPV4 Channel in Intestinal Physiology and Pathology.Journal of inflammation research · 2024Review
- Impact of Gut Microbiota on the Peripheral Nervous System in Physiological, Regenerative and Pathological Conditions.International journal of molecular sciences · 2023Review
- Impact of gut-peripheral nervous system axis on the development of diabetic neuropathy.Memorias do Instituto Oswaldo Cruz · 2023Article
- Role of the duodenal microbiota in functional dyspepsia.Neurogastroenterology and motility · 2022Review
- Potential Roles of Enterochromaffin Cells in Early Life Stress-Induced Irritable Bowel Syndrome.Frontiers in cellular neuroscience · 2022Review
- How can probiotic improve irritable bowel syndrome symptoms?World journal of gastrointestinal surgery · 2021Review
- Integrative analysis of the gut microbiome and metabolome in a rat model with stress induced irritable bowel syndrome.Scientific reports · 2021Article
- The emerging role of probiotics in neurodegenerative diseases: new hope for Parkinson's disease?Neural regeneration research · 2021Article
- Identification of potential biomarkers for abdominal pain in IBS patients by bioinformatics approach.BMC gastroenterology · 2021Article
- Disruption of Firmicutes and Actinobacteria abundance in tomato rhizosphere causes the incidence of bacterial wilt disease.The ISME journal · 2021Article
- Article
- The Infant-DerivedMicroorganisms · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsIrritable bowel syndrome (IBS) is linked to post-inflammatory and stress-correlated factors that cause changes in the perception of visceral events. Probiotic bacteria may be effective in treating IBS symptoms. Here, we have investigated whether early life administration of VSL#3, a mixture of 8 probiotic bacteria strains, protects against development of visceral hypersensitivity driven by neonatal maternal separation (NMS), a rat model of IBS.
methodsMale NMS pups were treated orally with placebo or VSL#3 from days 3 to 60, while normal, not separated rats were used as controls. After 60 days from birth, perception of painful sensation induced by colorectal distension (CRD) was measured by assessing the abdominal withdrawal reflex (score 0-4). The colonic gene expression was assessed by using the Agilent Whole Rat Genome Oligo Microarrays platform and confirmed by real time PCR.
resultsNMS rats exhibited both hyperalgesia and allodynia when compared to control rats. VSL#3 had a potent analgesic effect on CRD-induced pain without changing the colorectal compliance. The microarray analysis demonstrated that NMS induces a robust change in the expression of subsets of genes (CCL2, NOS3, THP1, NTRK1, CCR2, BDRKRB1, IL-10, TNFRSF1B, TRPV4, CNR1 and OPRL1) involved in pain transmission and inflammation. TPH1, tryptophan hydroxylase 1, a validated target gene in IBS treatment, was markedly upregulated by NMS and this effect was reversed by VSL#3 intervention.
conclusionsEarly life administration of VSL#3 reduces visceral pain perception in a model of IBS and resets colonic expression of subsets of genes mediating pain and inflammation. TRANSCRIPT PROFILING: Accession number of repository for expression microarray data is GSE38942 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE38942).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.